513000 | PD 98059 - CAS 167869-21-8 - Calbiochem

513000
No pudo obtenerse el precio
Minimum Quantity needs to be mulitiple of
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmar Disponibilidad a confirmar
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    Remaining : Will advise
      Se avisará
      Ver precios y disponibilidad
         CompararClick To Print This Page

      Overview

      Replacement Information

      Tabla espec. clave

      Fórmula empírica Nº CAS
      C₁₆H₁₃NO₃167869-21-8

      Precios y disponibilidad

      Número de referenciaDisponiblidad Embalaje Cant./Env. Precio Cantidad
      513000-10MG
      Comprobando disponibilidad...
      Disponibilidad a confirmar Disponibilidad a confirmar
      Suspendido
      Cantidades limitadas disponibles
      Debe confirmarse disponibilidad
        Remaining : Will advise
          Se avisará

          10 mg
          Recuperando precio...
          No pudo obtenerse el precio
          Minimum Quantity needs to be mulitiple of
          Al finalizar el pedido Más información
          Ahorró ()
           
          Solicitar precio
          513000-25MG
          Comprobando disponibilidad...
          Disponibilidad a confirmar Disponibilidad a confirmar
          Suspendido
          Cantidades limitadas disponibles
          Debe confirmarse disponibilidad
            Remaining : Will advise
              Se avisará

              25 mg
              Recuperando precio...
              No pudo obtenerse el precio
              Minimum Quantity needs to be mulitiple of
              Al finalizar el pedido Más información
              Ahorró ()
               
              Solicitar precio
              513000-5MG
              Comprobando disponibilidad...
              Disponibilidad a confirmar Disponibilidad a confirmar
              Suspendido
              Cantidades limitadas disponibles
              Debe confirmarse disponibilidad
                Remaining : Will advise
                  Se avisará

                  5 mg
                  Recuperando precio...
                  No pudo obtenerse el precio
                  Minimum Quantity needs to be mulitiple of
                  Al finalizar el pedido Más información
                  Ahorró ()
                   
                  Solicitar precio
                  Descripción
                  Visión de conjunto Selective, reversible, and cell-permeable inhibitor of MAP kinase kinase (MEK) that acts by inhibiting the activation of MAP kinase and subsequent phosphorylation of MAP kinase substrates. Pretreatment of PC-12 cells with PD 98059 completely blocks the 4-fold increase in MAP kinase activity produced by nerve growth factor (NGF; IC50 = 2 µM); however, it has no effect on NGF-dependent tyrosine phosphorylation of the p140trk receptor or its substrate Shc and does not block NGF-dependent activation of PI 3-kinase. Blocks LPS-induced activation of TNF-α gene expression. Inhibits cell growth and reverses the phenotype of ras-transformed BALB3T3 mouse fibroblasts and rat kidney cells. A 5 mg/ml solution of PD 98059 (Cat. No. 513001) in anhydrous DMSO is also available.
                  Número de catálogo 513000
                  Marca de familia Calbiochem®
                  Sinónimos 2ʹ-Amino-3ʹ-methoxyflavone, MEK Inhibitor V
                  Referencias bibliográficas
                  Referencias bibliográficas Means, T.K., et al. 2000. J. Leukoc. Biol. 67, 885.
                  Kültz, D., et al. 1998. J. Biol. Chem. 273, 13645.
                  Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 7686.
                  Langlois, W.J., et al. 1995. J. Biol. Chem. 270, 25320.
                  Pang, L., et al. 1995. J. Biol. Chem. 270, 13585.
                  Waters, S.B., et al. 1995. J. Biol. Chem. 270, 20883.
                  Información del producto
                  Número de CAS 167869-21-8
                  ATP Competitivo N
                  Formulario Pale yellow solid
                  Fórmula Hill C₁₆H₁₃NO₃
                  Fórmula química C₁₆H₁₃NO₃
                  Molar Mass 267.3
                  Reversible Y
                  Imagen fórmula estructural
                  Aplicaciones
                  Información biológica
                  Objetivo principal MAP kinase kinase (MEK)
                  Objetivo principal IC50 2 µM against NGF-induced increase in MAP kinase activity
                  Pureza ≥98% by HPLC
                  Información fisicoquímica
                  Permeabilidad celular Y
                  Solubilidad DMSO or MeOH
                  Dimensiones
                  Información de materiales
                  Información toxicológica
                  Información de seguridad según el GHS
                  Información de seguridad
                  Declaraciones de uso del producto
                  Información de almacenamiento y transporte
                  Código de envío Ambient Temperature Only
                  Toxicidad Standard Handling
                  Almacenamiento -20°C
                  Proteger de la luz Protect from light
                  No congelar No
                  Instrucciones especiales Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 4 months at -20°C.
                  Información sobre embalaje
                  Información de transporte
                  Información complementaria
                  Especificaciones

                  Documentation

                  Ficha datos de seguridad (MSDS)

                  Idiomas
                  Danmark Deutschland Ellas
                  English España France
                  Italia Korea Magyarország
                  Nederland  Norge Polska
                  Portugal Suomi Sverige
                  България

                  Certificados de análisis

                  CargoNúmero de lote
                  513000

                  Referencias bibliográficas

                  Visión general referencias
                  Means, T.K., et al. 2000. J. Leukoc. Biol. 67, 885.
                  Kültz, D., et al. 1998. J. Biol. Chem. 273, 13645.
                  Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 7686.
                  Langlois, W.J., et al. 1995. J. Biol. Chem. 270, 25320.
                  Pang, L., et al. 1995. J. Biol. Chem. 270, 13585.
                  Waters, S.B., et al. 1995. J. Biol. Chem. 270, 20883.

                  Citas

                  Título
                • Joao B. Oliveira, et al. (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Procedings of the National Academy of Science 104, 8953-8958.
                • Alexandra Thiel, Mira Heinonen, Johanna Rintahaka, Tuija Hallikainen, and Annabrita Hemmes, Dan A. Dixon, Caj Haglund, and Ari Ristimaki. (2006) EXPRESSION OF CYCLOOXYGENASE-2 IS REGULATED BY GSK-3 IN GASTRIC CANCER CELLS. Journal of Biological Chemistry in press,.
                • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
                • Alexandra Thiel, et al. (2006) Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells. Journal of Biological Chemistry 281, 4564-4569.
                • Bysani Chandrasekar, et al. (2005) The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-J. Journal of Biological Chemistry 280, 26263-26277.
                • Diane Gesty-Palmer, et al. (2005) b-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. Journal of Biological Chemistry 280, 32157-32167.
                • Renee M. Marshall, et al. (2005) Cyclin T1 expression is regulated by multiple signaling pathways and mechanisms during activation of human peripheral blood lymphocytes. Journal of Immunology 175, 6402-6411.
                • Wojciech Wojciechowski, et al. (2005) Enhanced Expression of CD20 in Human Tumor B Cells is Controlled Through ERK-Dependent Mechanisms. Journal of Immunology 174, 7859-7868.
                • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
                • Yona Goldshmit, et al. (2004) SOCS2 Induces Neurite Outgrowth by Regulation of Epidermal Growth Factor Receptor Activation. Journal of Biological Chemistry 279, 16349-16355.
                • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
                • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
                • Michael J. Cross, et al. (2002) The Shb Adaptor Protein Binds to Tyrosine 766 in the FGFR-1 and Regulates the Ras/MEK/MAPK Pathway via FRS2 Phosphorylation in Endothelial Cells. Molecular Biology of the Cell 13, 2881-2893.
                • Maryse Delehedde, et al. (2002) Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochemistry Journal 366, 235-244.
                • Silja Wessler, et al. (2000) Helicobacter pylori activates the histidine decarboxylase promoter through a mitogen-activated protein kinase pathway independent of pathogenicity island-encoded virulence factors. Journal of Biological Chemistry 275, 3629-3636.
                • Ficha técnica

                  Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

                  Revisión 21-January-2014 JSW
                  Sinónimos 2ʹ-Amino-3ʹ-methoxyflavone, MEK Inhibitor V
                  Descripción Selective, reversible, and cell-permeable inhibitor of MAP kinase kinase (MEK) that acts by inhibiting the activation of MAP kinase and subsequent phosphorylation of MAP kinase substrates (noncompetitive with respect to ATP). Pretreatment of PC-12 cells with PD 98059 completely blocks the 4-fold increase of MAP kinase activity produced by nerve growth factor (NGF; IC50 = 2 µM); however, it has no effect on NGF-dependent tyrosine phosphorylation of the pp140trk receptor or its substrate Shc and does not block NGF-dependent activation of PI 3-kinase. Inhibits cell growth and reverses the phenotype of ras-transformed BALB 3T3 mouse fibroblasts and rat kidney cells.
                  Formulario Pale yellow solid
                  Número de CAS 167869-21-8
                  Masa molar 267.3
                  Fórmula química C₁₆H₁₃NO₃
                  Fórmula estructural
                  Pureza ≥98% by HPLC
                  Solubilidad DMSO (20 mg/ml) or Methanol (0.7 mg/ml)
                  Almacenamiento -20°C
                  Protect from light
                  Do Not Freeze No
                  Special Instructions Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 4 months at -20°C.
                  Toxicidad Standard Handling
                  Referencias bibliográficas Means, T.K., et al. 2000. J. Leukoc. Biol. 67, 885.
                  Kültz, D., et al. 1998. J. Biol. Chem. 273, 13645.
                  Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 7686.
                  Langlois, W.J., et al. 1995. J. Biol. Chem. 270, 25320.
                  Pang, L., et al. 1995. J. Biol. Chem. 270, 13585.
                  Waters, S.B., et al. 1995. J. Biol. Chem. 270, 20883.
                  Cita
                • Joao B. Oliveira, et al. (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Procedings of the National Academy of Science 104, 8953-8958.
                • Alexandra Thiel, Mira Heinonen, Johanna Rintahaka, Tuija Hallikainen, and Annabrita Hemmes, Dan A. Dixon, Caj Haglund, and Ari Ristimaki. (2006) EXPRESSION OF CYCLOOXYGENASE-2 IS REGULATED BY GSK-3 IN GASTRIC CANCER CELLS. Journal of Biological Chemistry in press,.
                • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
                • Alexandra Thiel, et al. (2006) Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells. Journal of Biological Chemistry 281, 4564-4569.
                • Bysani Chandrasekar, et al. (2005) The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-J. Journal of Biological Chemistry 280, 26263-26277.
                • Diane Gesty-Palmer, et al. (2005) b-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. Journal of Biological Chemistry 280, 32157-32167.
                • Renee M. Marshall, et al. (2005) Cyclin T1 expression is regulated by multiple signaling pathways and mechanisms during activation of human peripheral blood lymphocytes. Journal of Immunology 175, 6402-6411.
                • Wojciech Wojciechowski, et al. (2005) Enhanced Expression of CD20 in Human Tumor B Cells is Controlled Through ERK-Dependent Mechanisms. Journal of Immunology 174, 7859-7868.
                • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
                • Yona Goldshmit, et al. (2004) SOCS2 Induces Neurite Outgrowth by Regulation of Epidermal Growth Factor Receptor Activation. Journal of Biological Chemistry 279, 16349-16355.
                • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
                • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
                • Michael J. Cross, et al. (2002) The Shb Adaptor Protein Binds to Tyrosine 766 in the FGFR-1 and Regulates the Ras/MEK/MAPK Pathway via FRS2 Phosphorylation in Endothelial Cells. Molecular Biology of the Cell 13, 2881-2893.
                • Maryse Delehedde, et al. (2002) Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochemistry Journal 366, 235-244.
                • Silja Wessler, et al. (2000) Helicobacter pylori activates the histidine decarboxylase promoter through a mitogen-activated protein kinase pathway independent of pathogenicity island-encoded virulence factors. Journal of Biological Chemistry 275, 3629-3636.